1. AstraZeneca and Amgen get optimistic phase 3 asthma drug results — Pfizer/BioNTech begin studies for third booster dose and development of vaccine for variants — Merck KGaA in biobucks pact with Debiopharm for next-gen cancer asset See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

What will they sell next?

Discussion in 'Exact Sciences' started by Anonymous, Jan 8, 2015 at 8:26 AM.

  1. Anonymous

    Anonymous Guest

    EXACT Sciences (NASDAQ:EXAS) COO Maneesh Arora sold 2,495 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $26.72, for a total transaction of $66,666.40. Following the completion of the transaction, the chief operating officer now directly owns 105,245 shares in the company, valued at approximately $2,812,146. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.


    EXACT Sciences (NASDAQ:EXAS) CEO Kevin T. Conroy sold 9,484 shares of the stock on the open market in a transaction dated Friday, January 2nd. The stock was sold at an average price of $26.72, for a total value of $253,412.48. Following the transaction, the chief executive officer now directly owns 223,214 shares of the company’s stock, valued at approximately $5,964,278. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.